According to the CDC, dengue is defined as a viral disease spread through mosquito bites. It is a mosquito-borne viral infection that causes symptoms such as a flu-like illness and, sometimes, a potentially lethal complication, called severe dengue. Severe dengue was previously known as dengue hemorrhagic fever, and it was first recognized in the 1950s, during dengue epidemics in the Philippines and Thailand.
According to the WHO, as of today, Asian and Latin American countries are affected most by the disease, and it has become a leading cause of hospitalization and death among children and adults in these regions. It was estimated that there are approximately 390 million dengue infections per year, of which 96 million manifest clinically (with any severity of disease). In another study, done by Brady OJ et al, it was estimated that 3.9 billion people, in 128 countries, are at risk of infection with dengue viruses. All these factors are contributing to the impact of dengue across the globe.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence